SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) — GBT Technologies Inc. (OTC PINK:Â GTCH) (“GBTâ€, or the â€œCompanyâ€), announced that GBT Tokenize (â€œGBT/Tokenize”) started research in the Kirlian Electrophotography imaging technique potentially aimed for inclusion within its qTerm device. GBT/Tokenizeâ€™s qTerm, is a human vitals device powered by AI and is aimed to measure human vitals with a touch of a finger.
GBT/Tokenize encourages public participation in its research. Scientists and researchers that are interested to participate in our research are welcome to send us their material for evaluation at email@example.com
The human body emits various radiations such as infrared, electromagnetic radiation, low level visible light and ultraviolet radiation. This human biofield carries unique information which can potentially be useful for diagnosing and predicting diseases. The various aspects of this biofield can be measured in order to identify organ and/or tissue dysfunctions and therefore potentially detect early stages of possible diseases. Early detection is essential to ensure proper treatment and care.
Kirlian Electrophotography technique is a photographic method to capture the phenomenon of electrical coronal discharges which can be used to produce a human’s organ biofield. The technique is based on shooting a high voltage charge through an object that is connected to a photographic plate. The resulting image typically includes a colored aura around the object. When performed on a human organÂ the aura is its biofield. The research will be focusing on using Kirlian imaging techniques for early disease diagnostics. GBT/Tokenize’s Machine Learning system is aimed to analyze the biofield data and possible detection of onset disease. Based on Kirlian images and patterns, GBT/Tokenize’s AI seeks to observe, study, analyze and ultimately alert physicians about possible underlyingÂ illnessesÂ or symptoms. If developed and commercialized, such a system can be efficient for remote telemedicine diagnostics and medical advice.
“We are excited to start new research for our qTerm device” stated Danny Rittman, GBT’s CTO. “This research is about the analysis of Kirlian electrophotography data in order to detectÂ an onset of possible illnesses.Â Kirlian imaging can produce a bio-energyÂ of human’s organs and can perform as a diagnostic tool. Using Kirlian imaging, we believe it is possible to produce aÂ measureÂ of human energy levels and examine changes in the energy distribution throughout the organ(s). We are attempting to determine if we can implementÂ Kirlian imaging for qTerm by means of producing a human’s finger aura (i.e. its biofield). Along with qTerm vitals measurement, the goal is to potentially provide a Kirilian image. In turn, using ourÂ Machine learning technology, we are seeking to develop an analysis of theÂ biofield and, in turn, provide aÂ diagnostic and potential medical issues classification. We believe this type of system, if fully developed and commercialized, could be very efficientÂ as additional diagnostic system. We commenced our research and we encourage public participation in this research and we will share our findings on our website qterm.me” continued Dr. Rittman.
Illustration of Kirlian photograph of a fingertip, 1989:
Actual Test imaging (for presentation purposes only):
Certain statements contained in this press release may constitute “forward-looking statements”. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( http://www.sec.gov ). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Companyâ€™s ability to raise capital on acceptable terms, if at all, the Companyâ€™s successful development of its products and the integration into its existing products and the commercial acceptance of the Companyâ€™s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release.
Dr. Danny Rittman, CTO
GBT Technologies Inc.
This article is for the purposes of solicitation subscriptions for this website. This website expects to generate new advertisement revenue resulting from the distribution of this article. The amount of which is unknown at this time. This website or it’s authors do not own any shares of GBT Technologies Inc (GTCH) and does not buy, sell, or trade any shares of (GTCH). This article does not provide a professional analysis of a (GTCH) financial position. (GTCH) financial position and all other information regarding the featured Company should be verified directly with (GTCH). Please read our full disclaimer for more detailed information.